Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: A surge in the use of semaglutide injection (Ozempic ® ) approved to treat type 2 diabetes (T2D) has led to a global supply shortage. We investigated contemporary user rates and clinical characteristics of semaglutide (Ozempic ® ) users in Denmark, and the extent of “off-label” prescribing for weight loss. Patients and Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic ® ) were included. We examined quarterly rates of new users and total user prevalences, using other glucagon-like peptide-1 receptor agonists and weight loss medications as comparison. We also investigated user characteristics including T2D, glucose control, comedications, and cardiorenal disease. Results: The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply. User prevalence increased to 91,626 users in Denmark in 2023. The proportion of semaglutide (Ozempic ® ) new users who had a record of T2D declined from 99% in 2018 to only 67% in 2022, increasing again to 87% in 2023. Among people with T2D who initiated semaglutide (Ozempic ® ) in 2023, 52% received antidiabetic polytherapy before initiation, 39% monotherapy, and 8% no antidiabetic therapy. Most T2D initiators had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol and 68% ≥ 53 mmol/mol despite use of antidiabetic medication, and 29% had established atherosclerotic cardiovascular disease or kidney disease. Conclusion: The use of semaglutide (Ozempic ® ) in Denmark has increased dramatically. Although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D. Conversely, most initiators with T2D had a clear medical indication for treatment intensification, and “off-label” use can only explain a minor part of the supply shortage. Keywords: drug utilization, epidemiology, anti-obesity drugs, glucose-lowering drugs, obesity, type 2 diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A surge in the use of GLP‐1RA has thus occurred in many countries over the last 3–4 years, even leading to periods of global supply shortage. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Population‐based studies from the United States (US) and Europe have documented substantial increases in anti‐obesity medication use during the last decade, 16 , 22 , 23 , 24 accelerating with the introduction of semaglutide and tirzepatide for weight loss. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A surge in the use of GLP‐1RA has thus occurred in many countries over the last 3–4 years, even leading to periods of global supply shortage. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Population‐based studies from the United States (US) and Europe have documented substantial increases in anti‐obesity medication use during the last decade, 16 , 22 , 23 , 24 accelerating with the introduction of semaglutide and tirzepatide for weight loss. 16”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 9×
“Among people initiating semaglutide (Ozempic ® ) who had a record of T2D, we further described the number and type of prior antidiabetic medications used within the last year, the most recent HbA1c value measured within the last year, and the presence of established hospital-diagnosed atherosclerotic cardiovascular di…”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“10 In contrast, there is less clear evidence for an effectiveness of GLP-1RA on primary prevention of cardiovascular disease, both for T2D 42 and obesity, although there is some indication that GLP-1RAs may reduce cardiovascular outcomes in people with T2D and multiple cardiovascular risk factors,…”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“…disease, both for T2D 42 and obesity, although there is some indication that GLP-1RAs may reduce cardiovascular outcomes in people with T2D and multiple cardiovascular risk factors, 8 reflected in “Class IIb”, “Level C” recommendations in the most recent European Society of Cardiology guidelines.”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 3×
“3,22 Since 2015, numerous large cardiovascular outcome trials have shown that GLP-1RAs including semaglutide reduce cardiovascular and renal complications in high-risk T2D patients and confer organ-protective effects beyond lowering glucose.”
BackgroundObesity Stigma: Important Considerations for Public Health
Puhl, R. M., & Heuer, C. A. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.159491 · Cited by 1,917 · cited 1×
“33 14 Indeed, many primary care physicians report strongly increasing demands from their patients, and it is well-known that such pressure can lead to inappropriate prescribing patterns.”
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431 · cited 4×
“15,19 Codes used for medications, diagnoses, procedures, and laboratory tests are shown in Supplementary Table 1.”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 1
- Iannone, 2023, Diabetes Obes Metab, 25, 2535, 10.1111/dom · doi:10.1111/dom
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Self-citationGLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16316 · Cited by 85
Self-citationGrauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00620-x · Cited by 79
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1455 · Cited by 61
Haykal, D., Hersant, B., Cartier, H., & Meningaud, J. (2024) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.16716 · Cited by 76
“The gaunt appearance, associated with the Semaglutide face, contrasts with the expected benefits of feeling healthier, leaving patients concerned about their facial esthetics [10].”
Figlioli, G., Piovani, D., Peppas, S., Pugliese, N., Hassan, C., Repici, A., Lleò, A., Aghemo, A., & Bonovas, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107401 · Cited by 68
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
A Closer Look at the Dermatological Profile of GLP-1 Agonists
Persson, C., Eaton, A. C., & MAYROVITZ, H. N. (2025) · Diseases · doi:10.3390/diseases13050127 · Cited by 57
“The suppression of food intake and resulting weight loss provides essential advantages for patients who struggle with obesity or complications from excessive weight [6].”
InfluentialAzab, M., & Pasina, L. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.011 · Cited by 33
Sørensen, M. S., Pottegård, A., Andersen, N. E., Thomsen, R. W., & Lundby, C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16222 · Cited by 18
Self-citationNikolis, A., Enright, K. M., Fabi, S. G., Somenek, M. T., Cartier, H., Avelar, L. E. T., Franco, J., Haddad, A., Angelo‐Khattar, M., Huang, J. C.-C., et al. (2025) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.70094 · Cited by 20
Thapaliya, K., Sweeting, A., Black, K. I., Poprzeczny, A. J., Mazza, D., & Grzeskowiak, L. E. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70026 · Cited by 17
“25,26 Given that GLP-1 receptor agonists are increasingly prescribed for off-label uses such as weight loss, as well as high rates of overweight and obesity among women of reproductive age, clinical practice guidelines are needed to support their safe and effective use in women in this age group.”
Increasing Postpartum Use of GLP-1 Receptor Agonists
Bliddal, M., Nohmie, G., Damkier, P., & Pottegård, A. (2025) · JAMA · doi:10.1001/jama.2025.20947 · Cited by 14
Self-citationHasselbalch, R. B., Andréa, M. K., Nolsøe, C. V., Hindborg, M., Yazdanfard, P. D. W., Sørensen, K. K., Blomberg, S. N. F., Christensen, H. C., Graff, C., Denholt, C. S., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101398 · Cited by 19
“30 However, these data were primarily from before the release of semaglutide for weight loss in Denmark.”
Fors, A., Forslund, T., Sundström, A., & Wettermark, B. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03823-9 · Cited by 19
“…prescribing of GLP-1 RAs, something which aligns with previous indications of an increasing off-label prescribing and misuse of GLP-1 RAs [28–31, 60 ], together with a The result further showed that the majority of patients who were dispensed their first GLP-1 RA received the drug within the…”
du Soulier, N., Pariente, A., Bezin, J., Grenet, G., Faillie, J.-L., & de Germay, S. (2025) · Value in Health · doi:10.1016/j.jval.2025.06.001 · Cited by 17
Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review
Mandal, L., Andersen, L. S., Luef, B. M., Tanvig, M. H., & Vinter, C. A. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.114836 · Cited by 15
Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Altabas, V., Orlović, Z., & Baretić, M. (2025) · Diabetology · doi:10.3390/diabetology6060052 · Cited by 10
Trends in the use of drugs with weight‐loss effect: Scandinavian study from 2017 to 2023
Ruiz, P. L., Hindenes, L. B., Karlstad, Ø., Nøkleby, K., Meyer, H. E., Mailhac, A. C., Ljung, R., Thomsen, R. W., & Furu, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16291 · Cited by 6
Self-citationKvist, A. V., Andersen, S. S., Vestergaard, P., & Viggers, R. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07950-6 · Cited by 6
TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends
Günaltay, M. M., & Kartal, N. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103082 · Cited by 8
Levy, M. E., Telis, N., Barrett, K. M. S., Bolze, A., Stoller, D. A., Chapman, C. N., Chahal, C. A. A., Judge, D. P., Olson, D. A., Grzymski, J. J., et al. (2024) · medRxiv · doi:10.1101/2024.10.31.24316494 · Cited by 7
“1,2 Ozempic has commonly been prescribed off-label, 26 resulting in many patients not receiving the high 2.4-mg dose recommended for weight loss.”
BackgroundInfluentialCosmetic Considerations of Semaglutide
Baggett, A. D., Saadi, C. C., Saadi, R. A., & Patel, V. (2025) · Cosmetics · doi:10.3390/cosmetics12050221 · Cited by 6
Gama, F. D. S., Ferreira, M. A., Segretti, N., Damião, M. C. F. C. B., Guimarães, C. R. W., Mascarello, A., & de Azevedo, H. F. Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02225 · Cited by 4
Momeni, P., Laverghetta, G., Ligatti, J., & Li, L. (2025) · Online Journal of Public Health Informatics · doi:10.2196/80660 · Cited by 5
Xu, Y., & Kuipers, O. P. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00132 · Cited by 5
Pattern of semaglutide prescription in a real-world Canadian patient cohort
Farahvash, A., Lee, M. C. M., Jain, R., & Jaakkimainen, L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.006 · Cited by 5
Seidel, D. U., & Bode, S. (2025) · HNO · doi:10.1007/s00106-025-01653-w · Cited by 4
Lauck, B. J., Colson, C. B., Bank, N. C., Trasolini, N. A., Waterman, B. R., Churchill, J. L., & Reynolds, A. W. (2026) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671251412408 · Cited by 2
“14 The influence of GLP-1RA on surgical outcomes and complications has also been previously explored in TSA patients with conflicting results.”
Avelar, L. E. T., Sarlos, P., Guarnieri, C., Alvarez, P., Juárez, G., Rossiere, N., Toro, V., Kamamoto, C. S. L., Gomes, R. T., Nogueira, A., et al. (2026) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s620566 · Cited by 3
“15 In the US 46.3% of physicians support prescribing it off-label.”
InfluentialFalster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70715 · Cited by 7
The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025Preprint
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339120 · Cited by 2
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?
Kumar, S., Olson, O., & Kellogg, T. A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01347-2 · Cited by 3
“GLP-1 receptor agonist prescribing patterns vary by coverage and country; however the number of prescriptions are increasing [61, 62 ].”
A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon
Sibarani, N. T., Simanjuntak, A. A., Simanjuntak, D. M. P., Tuba, S., Priyono, A., Sumaryono, B., & Sari, E. P. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.142019 · Cited by 1
Kreidieh, D., Ballout, R., Abutaima, R., Kharroubi, S. A., & Saleh, F. A. (2026) · BMC Public Health · doi:10.1186/s12889-026-27162-1 · Cited by 1
“In our study, 11.7% of respondents said they have used medication for weight loss purposes in the last 12 months, mostly Ozempic (50%), despite that the use of semaglutide (Ozempic) is not approved by the FDA for weight reduction without type 2 diabetes diagnosis [34].”
InfluentialDontamsetti, K. D., Aktar, R., & Peiris, M. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70461 · Cited by 2
Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025
Kildegaard, H., Andersen, J. H., Vinding, R., Kloppenborg, J. T., & Pottegård, A. (2026) · Obesity · doi:10.1002/oby.70234 · Cited by 1
Self-citationMiot, H. A. (2025) · Dermatologic Surgery · doi:10.1097/dss.0000000000004660 · Cited by 1
The unseen risk of Ozempic: NAION and vision damage
Saleem, N. U. A., Khan, M., Tague, C., & Akilimali, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004149 · Cited by 1
“An analysis of semaglutide use in Denmark between 2018 and 2023 revealed that the percentage of new users without a type 2 diabetes diagnosis rose from 1% in 2018 to 33% in 2022, suggesting a rise in off-label use for weight control [ 4 ] .”
Development and Exploitation of RiPPs technology for Peptide Engineering
Xu, Y. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1161821388
Physical activity promotes gut adaptation, responses to nutrients, and sensitivity to gut peptidesPreprint
Bæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653520
“23,24 Importantly, exercise combined with pharmacological treatment with GLP-1 receptor agonists (GLP-1RA), 25 effectively promotes additional weight-loss maintenance and potentiates fat-loss compared to groups treated with either GLP-1RA or one year exercise alone.”
Laursen, H. V. B., Udsen, F. W., Jensen, M. H., Vestergaard, P., & Johnsen, S. P. (2025) · medRxiv · doi:10.1101/2025.06.20.25328883
Rasmussen, L., Andersen, J. H., Kofoed‐Enevoldsen, A., Jensen, P. B., Madsen, G. K., Jűrgens, G., Pottegård, A., & Andersen, S. E. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70343
“44 Another limitation is the use of filled prescriptions as a proxy for drug use and the inclusion of hospital-based diagnoses only.”
Self-citationCastellana, E., Budau, P. M., & Chiappetta, M. R. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261422610 · Cited by 1
“25 In addition to improved glycemic control, newer pharma-cotherapies have demonstrated substantially greater effects on body weight compared with traditional agents.”
A Content Analysis of Web Pages on “Weight-Loss Injections”
Asuman, O. K. U. R. (2026) · Cerasus journal of medicine. · doi:10.70058/cjm.1852434
A Cross-Sectional Analysis of Plastic Surgery With GLP-1-Related Content on TikTok
Gupta, R., Patel, S. S., Bhagwat, A. M., Gupta, R., Xia, T. Y., Lund, H., & Kaswan, S. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag094
Unseen and untreated: implementing sarcopenic obesity care in Nordic general practice
Baygi, F., Haastrup, P., Buhl, S. F., Nielsen, J. B., Suetta, C., Rathleff, M. S., & Søndergaard, J. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1815247 · Cited by 1
“In contrast, Denmark lacks published prevalence studies, highlighting a national evidence gap that contributes to SO remaining a blind spot in primary care, where body mass index (BMI)-driven approaches overshadow the inclusion of muscle health and functional capacity.”
InfluentialSelf-citationCosmetic use of GLP‐1 receptor agonists: Ethical concerns amid drug shortages
Arfan, A., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70652
GLP-1 medications: use and interest in a representative survey of Finns
Jallinoja, P. T., Pietiläinen, K. H., & Chang, V. W. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02149-5 · Cited by 2
“Accordingly, demand has surged in several countries [15, 17 – 19], while traditional behavioural programmes, such Weight Watchers, have seen declining engagement and revenue [20].”
Hormonal Contraception and Initiation of Semaglutide Therapy
Bager, M. D., Wood-Kurland, H. K., Sørensen, K. K., Kragholm, K. H., Andersen, M. O., Torp-Pedersen, C. T. P., & Yazdanfard, P. D. W. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.24382
Gomon, Y. М., Колбин, А. С., Spichakova, E. A., & Reznik, V. A. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0022
Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia
Belančić, A., Štiglić, M. K., Fajkić, A., Jelaković, A., Pećin, I., Reiner, Ž., Jelaković, B., & Vitezić, D. (2026) · Journal of International Medical Research · doi:10.1177/03000605261470651
“20,21 Within this landscape, individual agents showed distinct adoption trajectories.”
Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents
Harbi, H., Thomsen, R. W., Lundby, C., Stidsen, J. V., Højlund, K., Ryg, J., Reilev, M., & Pottegård, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71308
Self-citationOff-label prescribing: evidence and ethics
Winter, G. (2026) · Journal of Prescribing Practice · doi:10.12968/jprp.2026.0096
The eye in the era of GLP-1 receptor agonists ‒ a narrative review of current evidence
Rusinek, H., Korniluk, J., Milusz, N., Dmoch, W., & Maciejewicz, P. (2026) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2026.3.8
李, 美., Zhou, C., & Zhou, J. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261492895
Risiken und therapeutische Optionen
Seidel, D. U., & Bode, S. (2026) · Deutsche Dermatologie · doi:10.1007/s15011-026-7421-y
Roland, N., Ernst, M., Linde, J. J., Rasmussen, L., & Pottegård, A. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101909
“28 A post hoc analysis confirmed this hypothesis, with use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and the ATC class containing tirzepatide being twice as high among females compared to males, whereas the remaining antidiabetic classes showed a predominantly male pattern of use…”
Self-citationZakeri, N., & Tolvanen, L. (2026) · Nutrients · doi:10.3390/nu18213524
Metadata
- Authors
- Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R.
- Affiliations
- Aarhus University (DK)
- University of Southern Denmark (DK)
- Danish Medicines Agency (DK)
- Corresponding author
- Thomsen, Reimar
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2024-04
- Volume
- Volume 16
- Pages
- 307-318
- ISSN
- 1179-1349 (ISSN-L)
- PMC
- PMC11057509
- OpenAlex
- W4395085097
- Cited by
- 60
- References
- 24
- Citations by year
- 2026: 25 · 2025: 29 · 2024: 6
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Novo Nordisk
- Sundhedsstyrelsen
- Diabetesforeningen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, Ozempic, off-label drug use, weight loss, type 2 diabetes, GLP-1 receptor agonists, drug use trends, drug shortages, glycemic control, HbA1c, atherosclerotic cardiovascular disease, kidney disease, Denmark, prescribing patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
